NICE recommends Sanofi's Sarclisa in multiple myeloma

15 October 2020
sanofi_big

The UK's National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending Sarclisa (isatuximab) alongside the existing treatments of pomalidomide and dexamethasone for adults with relapsed/refractory multiple myeloma who have received three prior lines of treatment and at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last treatment.

This recommendation from the cost-effectiveness watchdog for England and Wales means that the Sanofi (Euronext: SAN) drug will be made available to eligible patients through the National Health Service’s (NHS) Cancer Drugs Fund.

Sarclisa has been shown to improve progression-free survival by almost five months compared to existing treatment alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical